TY - JOUR T1 - Fluvastatin Inhibits HMG-CoA Reductase and Prevents Non–Small Cell Lung Carcinogenesis JF - Cancer Prevention Research JO - Cancer Prev Res (Phila) DO - 10.1158/1940-6207.CAPR-19-0211 AU - Zhang, Tianshun AU - Bai, Ruihua AU - Wang, Qiushi AU - Wang, Keke AU - Li, Xiang AU - Liu, Kangdong AU - Ryu, Joohyun AU - Wang, Ting AU - Chang, Xiaoyu AU - Ma, Weiya AU - Bode, Ann M. AU - Xia, Qingxin AU - Song, Yongping AU - Dong, Zigang Y1 - 2019/09/25 UR - http://cancerpreventionresearch.aacrjournals.org/content/early/2019/11/09/1940-6207.CAPR-19-0211.abstract N2 - Lung cancer is the leading cause of cancer-related death worldwide. However, promising agents for lung cancer prevention are still very limited. Identification of preventive targets and novel effective preventive agents is urgently needed for clinical applications. In this study, we found that fluvastatin targeted 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGCR), which a rate-limiting enzyme in the mevalonate pathway, and inhibited non–small cell lung cancer (NSCLC) tumorigenesis. Initially, we demonstrated that HMGCR is overexpressed in human lung adenocarcinoma tissues compared with normal tissues. Knockdown of HMGCR in NSCLC cells attenuated growth and induced apoptosis in vitro and in vivo. Furthermore, we found that fluvastatin, an inhibitor of HMGCR, suppressed NSCLC cell growth and induced apoptosis. Intriguingly, fluvastastin functions by inhibiting the HMGCR-driven Braf/MEK/ERK1/2 and Akt signaling pathways. Notably, fluvastatin attenuated tumor growth in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis and in a patient-derived xenograft lung tumor model. Overall, our findings suggest that fluvastatin might be promising chemopreventive or potential therapeutic drug against NSCLC tumorigenesis, providing hope for rapid clinical translation. ER -